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Erythropoietin supplement increases plasma lipoprotein lipase We reported in previous studies that plasma triglycer-
and hepatic triglyceride lipase levels in hemodialysis patients. ide levels, remnant-like particles-cholesterol (RLP-C),
Background. We reported in previous studies that plasma and -triglyceride (RLP-TG) levels were significantly
triglyceride levels, as well as remnant-like particles-cholesterol
lower in maintenance hemodialysis (HD) patients treated(RLP-C) and -triglyceride (RLP-TG) levels, were significantly
with erythropoietin (EPO) than in HD patients notlower in maintenance hemodialysis (HD) patients treated with
erythropoietin (EPO) than in HD patients treated without treated with EPO. Pollock et al reported that a significant
EPO. However, little is known about the mechanisms underly- reduction occurred in both total serum cholesterol levels
ing the improvements in abnormal RLP metabolism in HD and triglyceride levels during the course of EPO therapy
patients. This study investigates whether EPO supplement
in HD patients [1]. However, little is known about thetherapy in cases of uremic anemia increases the plasma lipopro-
mechanisms underlying the improvements in abnormaltein lipase (LPL) and hepatic triglyceride lipase (HTGL) levels
RLP metabolism in HD patients. This study investigatesin HD patients.
Methods. Twenty HD patients who had not previously re- whether EPO supplement therapy in cases of uremic
ceived EPO were divided into two groups according to the anemia increases the plasma lipoprotein lipase (LPL) and
stage of HD: 12 at the initial stage, defined as a mean HD hepatic triglyceride lipase (HTGL) levels in HD patients.
duration of 0.35 6 0.68 months (range of 0 to 2.47 months),
and 8 at the maintenance stage, defined as a mean HD duration
of 114.1 6 91.9 months (range of 13.0 to 253.9 months). Fasting METHODS
plasma was collected from the HD patients prior to the start
Twenty HD patients who had not previously receivedof the EPO supplement therapy and at one month after the
EPO were divided into two groups according to the stagetherapy. RLP-C levels were determined using a RLP-C JIMRO
II kit. Fasting plasma was also collected from the HD patients of HD: 12 HD patients (9 males and 3 females) at the
10 minutes after an intravenous injection of heparin (30 U/kg initial stage and 8 HD patients (4 males and 4 females)
body wt). Plasma LPL levels were determined using an enzyme at the maintenance stage. The 12 HD patients at theimmunoassay, and HTGL levels were determined using a modi-
initial stage ranged in age from 38 to 73 years, with anfied version of the Hernell et al method.
average age of 56.3 6 10.9 years and a mean HD durationResults. Plasma RLP-C levels showed a tendency to de-
of 0.35 6 0.68 months (range of 0 to 2.47 months). Increase after the start of the EPO supplement therapy in HD
patients at the maintenance stage. Plasma LPL levels were contrast, the eight HD patients at the maintenance stage
significantly higher in the two groups of HD patients one month ranged in age from 43 to 77 years, with an average age
after the start of the EPO supplement therapy than in the same of 61.0 6 12.6 years and a mean HD duration of 114.1 6patients prior to the start of the EPO supplement therapy.
91.9 months (range of 13.0 to 253.9 months). The numberPlasma HTGL levels were significantly higher in HD patients
of HD patients with diabetes mellitus was three in theat the maintenance stage one month after the start of the EPO
initial stage group and two in the maintenance stage group.supplement therapy than in HD patients at the maintenance
stage prior to the start of the EPO supplement therapy. Fasting plasma was collected from HD patients prior
Conclusions. The results of this study suggest that the EPO to the start of the EPO supplement therapy and at one
supplement therapy may reduce plasma RLP-C levels by in- month after the therapy. An EPO dose of 4500 IU/weekcreasing the plasma LPL and HTGL levels in maintenance-
was used for the study. RLP-C levels were determinedstage HD patients.
using a RLP-C JIMRO II kit [2]. Fasting plasma was
also collected from the HD patients 10 minutes after
an intravenous injection of heparin (30 U/kg body wt).Key words: atherosclerosis, remnant-like particles-cholesterol, uremic
anemia. Plasma LPL levels were determined using an enzyme
immunoassay, and HTGL levels were determined using a 1999 by the International Society of Nephrology
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Fig. 1. Changes in plasma lipoprotein lipase
(LPL) levels prior to and one month after the
start of the erythropoietin (EPO) supplement
therapy in hemodialysis (HD) patients. (A)
HD patients at the initial stage (N 5 12). (B)
HD patients at the maintenance stage (N 5 8).
*P , 0.05 vs. plasma LPL levels prior to the
start of the EPO supplement therapy in HD
patients. Also, mean values and sd are given.
Fig. 2. Changes in plasma hepatic triglyceride
lipase (HTGL) levels prior to and one month
after the start of the erythropoietin (EPO) sup-
plement therapy in hemodialysis (HD) patients.
(A) HD patients at the initial stage (N 5 12).
(B) HD patients at the maintenance stage
(N 5 8). *P , 0.05 vs. plasma HTGL levels
prior to the start of the EPO supplement ther-
apy in HD patients. Also, mean values and
sd are given.
modified version of the Hernell, Egelrud, and Olivecrona the EPO supplement therapy in cases of uremic anemia
in HD patients in the maintenance stage group (P 5method [3]. The separation of RLP as the unbound frac-
0.0518). No significant differences were found betweention from the plasma was performed using an immunoaf-
plasma RLP-C levels prior to and one month after thefinity gel mixture containing anti-apoB 100 and anti-
start of the EPO supplement therapy in HD patients inapoA1 monoclonal antibodies [2]. Clinical laboratory
the initial stage group. Plasma LPL levels were signifi-data were measured using standard procedures.
cantly higher in the two groups of HD patients one month
Statistical analysis after the start of the EPO supplement therapy than in
the two groups of HD patients prior to the start of theAll values were expressed as mean 6 sd. Statistical
EPO supplement therapy (Fig. 1 A, B). Plasma HTGLanalysis of the data was done using Student’s t-test or paired
levels were significantly higher in HD patients in thet-test. Statistical significance was defined as a P , 0.05.
maintenance stage group one month after the start of
the EPO supplement therapy (Fig. 2B). No significant
RESULTS differences were found between plasma HTGL levels
No significant differences were found between red prior to and one month after the start of the EPO supple-
blood cell count (RBC) or in hemoglobin (Hb) and he- ment therapy in HD patients in the initial stage group
matocrit (Ht) levels in HD patients in the initial stage (Fig. 2A). No significant relationship was found between
group compared with the maintenance stage group prior changes in RBC, Hb, and Ht levels and changes in plasma
to the start of EPO supplement therapy. Plasma RLP-C LPL and HTGL levels in the two groups of HD patients
one month after the start of the EPO supplement therapy.levels showed a tendency to decrease after the start of
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DISCUSSION 0.68 months after the start of HD. Patients in this group
still had appetites below normal levels and irregular foodRLP appears to be an atherogenic lipoprotein, and
intake (data not shown). In summary, EPO supplementthus, the postprandial increase observed in remnant lipo-
therapy was found to increase the plasma LPL andproteins may represent an atherosclerotic risk factor and
HTGL levels in maintenance stage HD patients.may play a role in causing thrombotic complications by
stimulating platelets in patients with remnant hyperlipo- Reprint requests to Tetsuya Goto, M.D., Department of Internal
Medicine, Kodama Hospital, 12-1, Esashi Machi, Wakayama City, Wa-proteinemia [4, 5]. Increased levels of RLP may be a risk
kayama, 640-8335, Japan.factor for atherosclerosis in HD patients [6]. In addition,
both LPL and HTGL are involved in RLP-C metabolism.
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